Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifei Xiaoji Wan for Early Stage Lung Adenocarcinoma
NCT06387134Recruiting
- Sponsor
- Henan University of Chinese Medicine
- Start
- Dec 2022
- Primary completion
- Jan 2025
- Modality
- NPI (Non-Pharmacological Intervention), Herbal Formulation
- Countries
- 1
01
Overview
Randomised, open-label trial of Lifei Xiaoji Pill in lung adenocarcinoma (2 arms), sponsored by Henan University of Chinese Medicine. Primary endpoints: Lung Cancer Quality of Life Scale at 2 months, TCM symptoms and syndromes at 2 months and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
Lifei Xiaoji Pill
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06387134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06387134.